{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:27:05Z","timestamp":1767706025447,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2018,10,24]]},"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Post<jats:bold>-<\/jats:bold>transplant lymphoproliferative disorder (PTLD) is a recognised complication of solid and haematopoietic stem cell transplant. It consists of a heterogeneous group of lymphoid neoplasms that arises secondary to post-transplant immunosuppression. Although there is no definite standard of care for the optimal treatment for PTLD, rituximab, a monoclonal antibody, with and\/or without chemotherapy (usually CHOP=cytoxan, doxorubicin, vincristine, prednisone) has become a routine part of the treatment of any CD20 (+) PTLD, with response rates similar to chemotherapy with decreased toxicity. A rare and often lethal, complication of rituximab therapy for PTLD is bowel perforation secondary to tumour lysis of lymphoma involving the intestine. A small number of cases of bowel perforation have been reported, with very few documented survivors. The risk for recurrent perforation in the setting of ongoing rituximab treatment is unknown. There is sparse data supporting how to best treat the survivors.<\/jats:p>","DOI":"10.1136\/bcr-2018-226666","type":"journal-article","created":{"date-parts":[[2018,12,18]],"date-time":"2018-12-18T17:19:47Z","timestamp":1545153587000},"page":"e226666","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder"],"prefix":"10.1136","volume":"11","author":[{"given":"Brianne J","family":"Sullivan","sequence":"first","affiliation":[{"name":"Department of Surgery, Mount Sinai Health System, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace J","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mount Sinai Health System, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Sara","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mount Sinai Health System, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"2025082803545013000_11.1.e226666.1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12288-017-0799-7","article-title":"Monomorphic post-transplant lymphoproliferative disorder after kidney transplantation and hematopoietic stem cell transplantation: clinicopathological characteristics, treatments and prognostic factors","volume":"33","author":"Fu","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2025082803545013000_11.1.e226666.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2006.00284.x"},{"key":"2025082803545013000_11.1.e226666.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1062-1"},{"key":"2025082803545013000_11.1.e226666.4","doi-asserted-by":"crossref","unstructured":"Singavi AK , Harrington AM , Fenske TS . In: Evens AM , Evens AM , Blum KA , Post-transplant Lymphoproliferative Disorders, in Non-Hodgkin Lymphoma: pathology, imaging, and current therapy. Cham: Springer International Publishing, 2015:305\u201327.","DOI":"10.1007\/978-3-319-13150-4_13"},{"key":"2025082803545013000_11.1.e226666.5","doi-asserted-by":"crossref","unstructured":"Bishnoi R , Bajwa R , Franke AJ , et al . Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients. Exp Hematol Oncol 2017;6.doi:10.1186\/s40164-017-0087-0","DOI":"10.1186\/s40164-017-0087-0"},{"key":"2025082803545013000_11.1.e226666.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0377"},{"key":"2025082803545013000_11.1.e226666.7","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902934944"},{"key":"2025082803545013000_11.1.e226666.8","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200202270-00038"},{"key":"2025082803545013000_11.1.e226666.9","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/MPG.0b013e3182519cfc","article-title":"Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder","volume":"56","author":"Kutsch","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025082803545013000_11.1.e226666.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4961"},{"key":"2025082803545013000_11.1.e226666.11","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1097\/MJT.0b013e3181c08042","article-title":"Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab","volume":"17","author":"Muzaffar","year":"2010","journal-title":"Am J Ther"},{"key":"2025082803545013000_11.1.e226666.12","first-page":"1202","article-title":"[Post transplant lymphoproliferative disorder (PTLD)-10 years follow-up]","volume":"68","author":"Ignacak","year":"2011","journal-title":"Przegl Lek"},{"key":"2025082803545013000_11.1.e226666.13","doi-asserted-by":"crossref","first-page":"358","DOI":"10.9738\/INTSURG-D-13-00270.1","article-title":"Surgical management of perforated gastrointestinal posttransplantation lymphoproliferative disorder after heart transplantation","volume":"100","author":"Osawa","year":"2015","journal-title":"Int Surg"},{"key":"2025082803545013000_11.1.e226666.14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/TP.0b013e3182584854","article-title":"Surgical management of gastrointestinal posttransplant lymphoproliferative disorders in liver transplant recipients","volume":"94","author":"Cruz","year":"2012","journal-title":"Transplantation"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bcr-2018-226666","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-226666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:54:57Z","timestamp":1756378497000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-226666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12,13]]},"published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1136\/bcr-2018-226666"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-226666","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}